Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 7:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Gastrointestinal Health
Interventions
Bacillus (Shouchella) clausii CSI08, Placebo
Dietary Supplement · Other
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Fort Collins, Colorado
Not listed Phase 2 Interventional Accepts healthy volunteers

Fecal Transplant for Relapsing C. Difficile Infection

NCT01703494
Conditions
Clostridium Difficile
Interventions
Fecal Microbiota Transplantation, Sham Fecal Microbiota Transplantation
Biological
Lead sponsor
Colleen Kelly
Other
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
The Bronx, New York • Providence, Rhode Island
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Processing on Food Reward

NCT06017986
Conditions
Metabolic Diseases
Interventions
Ultra-processed food - Picture Set Meal, Minimally Processed Food - Picture Set Meal
Other
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
18 Years to 45 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Roanoke, Virginia
Conditions
Solid Tumors
Interventions
Binimetinib only treatment, Encorafenib only Treatment, Encorafenib & Binimetinib Treatment, Treatment of Encorafenib & Binimetinib & Ribociclib, Treatment of Encorafenib & Binimetinib & Cetuximab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Atlanta, Georgia • Boston, Massachusetts + 5 more
Conditions
Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions
Ocrelizumab (US), Ocrelizumab (EU), ABP 692
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
27
States / cities
Mobile, Alabama • Scottsdale, Arizona • Carlsbad, California + 24 more
Conditions
Pain, Postoperative
Interventions
XaraColl, Placebo
Drug · Other
Lead sponsor
Innocoll
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
24
States / cities
Anniston, Alabama • Birmingham, Alabama • Anaheim, California + 19 more
Conditions
Atopic Dermatitis
Interventions
Tralokinumab
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
29
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 24 more
Conditions
Chronic Spontaneous Urticaria
Interventions
barzolvolimab, Standard of Care
Biological · Other
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 32 more
Conditions
Pain, Postoperative
Interventions
XaraColl, Placebo
Drug · Other
Lead sponsor
Innocoll
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
23
States / cities
Mobile, Alabama • Sheffield, Alabama • Phoenix, Arizona + 18 more
Conditions
Relapsed or Refractory Hematologic Malignancies
Interventions
Trichostatin A
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Lafayette, Indiana • Hackensack, New Jersey + 1 more
Recruiting No phase listed Observational Accepts healthy volunteers

Optimize Pediatric OCT Imaging

NCT06139523
Conditions
Retinal Disease, Glaucoma, Optic Nerve Diseases
Interventions
Investigational contact OCT system, Investigational noncontact OCT system:
Device
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Crohn's Disease, Perianal Fistula
Interventions
Mirikizumab, Fistula Tract Curettage and Closure
Drug · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Louis, Missouri • New York, New York
Conditions
Eosinophilic Esophagitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Idaho Falls, Idaho • Chicago, Illinois • Urbana, Illinois + 11 more
Conditions
Pain, Postoperative, Abdominoplasty
Interventions
Bupivacaine Hydrochloride, Placebo collagen-matrix implant
Combination Product
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Pasadena, California • Dayton, Ohio • Bellaire, Texas + 1 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Impact of Grapefruit Juice on the Response to Clopidogrel

NCT00817999
Conditions
Healthy
Interventions
Grapefruit juice, Clopidogrel 75 mg/day, Clopidogrel 300 mg
Dietary Supplement · Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 40 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Completed Phase 1Phase 2 Interventional Results available

Salvage Peanut Oral Immunotherapy Study

NCT03251508
Conditions
Peanut Allergy
Interventions
Peanut OIT
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
HIV Infections, Tuberculosis
Interventions
Atazanavir, Rifampin, Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2007
U.S. locations
3
States / cities
Palo Alto, California • Columbus, Ohio • Nashville, Tennessee
Conditions
Seizures, Epilepsy, Seizure Disorder
Interventions
ANT recording and stimulation
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Glioma
Interventions
[11C]Acetate Brain Imaging
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Allergic Rhinitis
Interventions
Dupilumab, Timothy Grass SCIT, Placebo matching dupilumab, Placebo matching SCIT
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Los Angeles, California • Mountain View, California • Walnut Creek, California + 9 more
Conditions
Epilepsy
Interventions
Investigational Medicinal Product (MR1), Investigational Medicinal Product (MR2), Investigational Medicinal Product (MR3), Investigational Medicinal Product (MR4), Investigational Medicinal Product (MR5), Investigational Medicinal Product (IR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 2 Interventional Results available

A Research Study for Patients With Overactive Bladder

NCT00168454
Conditions
Overactive Bladder, Urinary Incontinence
Interventions
botulinum toxin Type A, Placebo
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 85 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania